SELAS PHARMACIE DE MITTELHAUSEN : revenue, balance sheet and financial ratios

SELAS PHARMACIE DE MITTELHAUSEN is a French company founded 17 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in WINGERSHEIM LES QUATRE BANS (67170), this company of category PME shows in 2017 a revenue of 1.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELAS PHARMACIE DE MITTELHAUSEN (SIREN 507642320)
Indicator 2024 2023 2019 2018 2017 2016
Revenue N/C N/C N/C N/C 1 485 905 € 1 538 604 €
Net income 82 971 € 81 030 € 777 239 € 74 608 € 84 088 € 92 601 €
EBITDA N/C N/C N/C N/C 124 192 € 176 155 €
Net margin N/C N/C N/C N/C 5.7% 6.0%

Revenue and income statement

In 2024, SELAS PHARMACIE DE MITTELHAUSEN generates positive net income of 83 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 93 k€ -> 83 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

82 971 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 9%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 92%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

8.58%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

91.52%

Solvency indicators evolution
SELAS PHARMACIE DE MITTELHAUSEN

Sector positioning

Debt ratio
8.58 2024
2019
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Excellent

In 2024, the debt ratio of SELAS PHARMACIE DE MITTEL... (8.58) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
91.52% 2024
2019
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent +16 pts over 3 years

In 2024, the financial autonomy of SELAS PHARMACIE DE MITTEL... (91.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 83.02. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

83.023

Liquidity indicators evolution
SELAS PHARMACIE DE MITTELHAUSEN

Sector positioning

Liquidity ratio
83.02 2024
2019
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Watch -38 pts over 3 years

In 2024, the liquidity ratio of SELAS PHARMACIE DE MITTEL... (83.02) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELAS PHARMACIE DE MITTELHAUSEN

Positioning of SELAS PHARMACIE DE MITTELHAUSEN in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of SELAS PHARMACIE DE MITTELHAUSEN is estimated at 1 158 336 € (range 806 647€ - 1 732 937€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
806k€ 1158k€ 1732k€
1 158 336 € Range: 806 647€ - 1 732 937€
NAF 5 année 2024

Valuation method used

Net Income Multiple
82 971 € × 14.0x = 1 158 337 €
Range: 806 647€ - 1 732 938€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELAS PHARMACIE DE MITTELHAUSEN with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELAS PHARMACIE DE MITTELHAUSEN

What is the revenue of SELAS PHARMACIE DE MITTELHAUSEN ?

The revenue of SELAS PHARMACIE DE MITTELHAUSEN in 2017 is 1.5 M€.

Is SELAS PHARMACIE DE MITTELHAUSEN profitable?

Yes, SELAS PHARMACIE DE MITTELHAUSEN generated a net profit of 83 k€ in 2024.

Where is the headquarters of SELAS PHARMACIE DE MITTELHAUSEN ?

The headquarters of SELAS PHARMACIE DE MITTELHAUSEN is located in WINGERSHEIM LES QUATRE BANS (67170), in the department Bas-Rhin.

Where to find the tax return of SELAS PHARMACIE DE MITTELHAUSEN ?

The tax return of SELAS PHARMACIE DE MITTELHAUSEN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELAS PHARMACIE DE MITTELHAUSEN operate?

SELAS PHARMACIE DE MITTELHAUSEN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.